Literature DB >> 33519922

The Skeleton of Lateral Meningocele Syndrome.

Ernesto Canalis1.   

Abstract

Notch (Notch1 through 4) are transmembrane receptors that determine cell differentiation and function, and are activated following interactions with ligands of the Jagged and Delta-like families. Notch has been established as a signaling pathway that plays a critical role in the differentiation and function of cells of the osteoblast and osteoclast lineages as well as in skeletal development and bone remodeling. Pathogenic variants of Notch receptors and their ligands are associated with a variety of genetic disorders presenting with significant craniofacial and skeletal manifestations. Lateral Meningocele Syndrome (LMS) is a rare genetic disorder characterized by neurological manifestations, meningoceles, skeletal developmental abnormalities and bone loss. LMS is associated with NOTCH3 gain-of-function pathogenic variants. Experimental mouse models of LMS revealed that the bone loss is secondary to increased osteoclastogenesis due to enhanced expression of receptor activator of nuclear factor kappa B ligand by cells of the osteoblast lineage. There are no effective therapies for LMS. Antisense oligonucleotides targeting Notch3 and antibodies that prevent the activation of NOTCH3 are being tested in preclinical models of the disease. In conclusion, LMS is a serious genetic disorder associated with NOTCH3 pathogenic variants. Novel experimental models have offered insight on mechanisms responsible and ways to correct the disease.
Copyright © 2021 Canalis.

Entities:  

Keywords:  Lehman syndrome; Notch; genetic disorders; lateral meningocele syndrome; osteoblast; osteoclast; osteoporosis

Year:  2021        PMID: 33519922      PMCID: PMC7841456          DOI: 10.3389/fgene.2020.620334

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  119 in total

Review 1.  Beyond γ-secretase activity: The multifunctional nature of presenilins in cell signalling pathways.

Authors:  Stephen P Duggan; Justin V McCarthy
Journal:  Cell Signal       Date:  2015-10-21       Impact factor: 4.315

2.  An antibody to Notch3 reverses the skeletal phenotype of lateral meningocele syndrome in male mice.

Authors:  Jungeun Yu; Christian W Siebel; Lauren Schilling; Ernesto Canalis
Journal:  J Cell Physiol       Date:  2019-06-12       Impact factor: 6.384

3.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.

Authors:  Y Y Kong; H Yoshida; I Sarosi; H L Tan; E Timms; C Capparelli; S Morony; A J Oliveira-dos-Santos; G Van; A Itie; W Khoo; A Wakeham; C R Dunstan; D L Lacey; T W Mak; W J Boyle; J M Penninger
Journal:  Nature       Date:  1999-01-28       Impact factor: 49.962

4.  High- and low-dose OPG-Fc cause osteopetrosis-like changes in infant mice.

Authors:  Renee Bargman; Ram Posham; Adele Boskey; Erin Carter; Edward DiCarlo; Kostas Verdelis; Cathleen Raggio; Nancy Pleshko
Journal:  Pediatr Res       Date:  2012-08-27       Impact factor: 3.756

Review 5.  Neurosurgical Management of Lateral Meningocele Syndrome: A Clinical Update for the Pediatric Neurosurgeon.

Authors:  Joshua A Cuoco; Brendan J Klein; Christopher M Busch; Hailey L Gosnell; Ayesha Kar; Eric A Marvin; Lisa S Apfel
Journal:  Pediatr Neurosurg       Date:  2019-12-13       Impact factor: 1.162

6.  The lateral meningocele syndrome mutation causes marked osteopenia in mice.

Authors:  Ernesto Canalis; Jungeun Yu; Lauren Schilling; Siu-Pok Yee; Stefano Zanotti
Journal:  J Biol Chem       Date:  2018-07-24       Impact factor: 5.157

Review 7.  More complicated than it looks: assembly of Notch pathway transcription complexes.

Authors:  R A Kovall
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

8.  Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover.

Authors:  Christy J Fryer; J Brandon White; Katherine A Jones
Journal:  Mol Cell       Date:  2004-11-19       Impact factor: 17.970

9.  CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.

Authors:  Volker Limmroth; Frederik Barkhof; Nuket Desem; Mark P Diamond; George Tachas
Journal:  Neurology       Date:  2014-09-19       Impact factor: 9.910

Review 10.  Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation.

Authors:  Jin Hee Park; Na Kyung Lee; Soo Young Lee
Journal:  Mol Cells       Date:  2017-10-17       Impact factor: 5.034

View more
  2 in total

1.  Activation of Notch3 in osteoblasts/osteocytes causes compartment-specific changes in bone remodeling.

Authors:  Ernesto Canalis; Stefano Zanotti; Lauren Schilling; Tabitha Eller; Jungeun Yu
Journal:  J Biol Chem       Date:  2021-03-24       Impact factor: 5.157

2.  Use of antisense oligonucleotides to target Notch3 in skeletal cells.

Authors:  Ernesto Canalis; Michele Carrer; Tabitha Eller; Lauren Schilling; Jungeun Yu
Journal:  PLoS One       Date:  2022-05-10       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.